Over the course of the last year, the prices of vital cancer-treating pharmaceuticals have decreased substantially in India, according to The National Pharmaceutical Pricing Authority (NPPA). In a ‘Tweet’, the drug pricing regulator relayed that there has been “a significant price reduction in cancer drug prices since March 2017.”
Pharmaceutical companies which can boast a decrease in the cancer drug prices include Iressa of AstraZeneca Pharma India; Dr. Reddy’s laboratories’ Grafeel; Natco, and Emcure pharmaceuticals, among many others.
Depending on the company, the price reductions range from 86% to 13%. A result of this positive news is that more individuals in need of the life-saving drugs may obtain them at more affordable prices.
According to the Times of India, price reductions were also applied to a dozen various diabetes medications. Price reductions range from 42% to 13%.
Because healthcare is a human right which should remain affordable to all, the NPPA has begun investigating 24 different hospitals that have received patient care complaints about being over-charged.
While the world deserves to know that the affliction of cancer can be benefited through dietary and lifestyle changes, such as adopting an alkaline forming, plant-based diet and improving one’s mental patterns and exercise regime, this positive development is worth reporting.
What are your thoughts? Please comment below and share this news!
This article (Prices Of Cancer Drugs In India Have Decreased By Dramatic 86%) is free and open source. You have permission to republish this article under a Creative Commons license with attribution to the author and TrueActivist.com
